EP2215059A2 - Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2 - Google Patents
Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2Info
- Publication number
- EP2215059A2 EP2215059A2 EP08833836A EP08833836A EP2215059A2 EP 2215059 A2 EP2215059 A2 EP 2215059A2 EP 08833836 A EP08833836 A EP 08833836A EP 08833836 A EP08833836 A EP 08833836A EP 2215059 A2 EP2215059 A2 EP 2215059A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- alkyl
- aryl
- mmol
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- Novel heteroaryl substituted acetone derivatives suitable for the inhibition of phospholipase A 2
- the present invention relates to novel heteroaryl-substituted acetone derivatives which inhibit the enzyme phospholipase A 2 . These compounds are useful as medicaments for the prevention and treatment of diseases caused by the increased activity of this enzyme, such as inflammation, pain, fever, allergies, asthma, psoriasis and endotoxin shock.
- phospholipase A 2 summarizes the large and diverse group of enzymes that cleave phospholipids at the sn-2 position to form free fatty acids and lysophospholipids.
- the released fatty acid is arachidonic acid, it can be metabolized via the cyclooxygenase route to the prostaglandins and thromboxanes and via the lipoxygenase pathways to the leukotrienes and other hydroxylated fatty acids.
- the prostaglandins are significantly involved in the development of pain and fever, as well as inflammatory reactions.
- Leukotrienes are important mediators in inflammatory processes and in anaphylactic and allergic processes.
- the lysophospholipids formed by the phospholipase A 2 possess cell-damaging properties. Lysophosphatidylserine leads to the release of the histamine involved in allergic processes.
- lysophosphatidylcholine is metabolized to the platelet-activating factor (PAF), which is also an important mediator in, for example, inflammation. training processes.
- PAF platelet-activating factor
- Inhibitors of the cytosolic phospholipase A 2 are known in the prior art.
- document WO 2004/069797 discloses heteroaryl-substituted acetone derivatives which inhibit the enzyme phospholipase A 2 .
- Q is R 1 , OR 1 , SR 1 , SOR 1 , SO 2 R 1 , NR 9 R 1 or a straight chain Ci_ 3 i-alkyl or C 2 - 3 i alkenyl or alkynyl radical which is denoted by 1 or 2 radicals, independently selected from O, S, SO, SO 2 , NR 9 and aryl, which may be substituted by 1 or 2 substituents R 4, may be interrupted, and with 1-4 Ci_ 6 alkyl radicals and / or 1 or 2 aryl radicals may be substituted, wherein the aryl radicals may be substituted by 1 or 2 substituents R 4 ;
- Ar is an aryl radical which may be substituted by 1 or 2 substituents R 4 ;
- X is N or CR 5 ;
- R 1 is H or an aryl radical which may be substituted by 1 or 2 substituents R 4 ;
- R 2 and R 3 a) independently represent H, CI_ 6 alkyl, C 2 - are W, or b) together with the carbon atoms to which they are attached - 6 alkenyl, C 2 - 6 alkynyl, or R 7 , represent a 5- or 6-membered aromatic or heteroaromatic ring which may be substituted by 1 or 2 substituents R 4 ;
- R 4 represents Ci_6-alkyl, halogen, CF 3, CN, NO 2, OR 9, S (O) 0 R 9, COR 9, COOR 9, CONR 9 R 10, SO 3 R 9, SO 2 NR 9 R 10 , Tetrazolyl or R 7 -W;
- R 5 is H or R 4 ;
- R 7 is Ci- 6 alkyl, C 2 - 6 alkenyl or C 2 - 6 alkynyl; - A -
- R is H, CI_ 6 alkyl or aryl
- R 10 is H or C 2 - 6 alkyl
- W is COOH, SO 3 H or tetrazolyl
- o 0, 1 or 2;
- Y stands for CR 12
- R 12 is selected from the group comprising 3-methyl-l, 2,4-oxadiazol-5-yl and / or COR 13 ,
- R, 13 is selected from the group comprising CF 3 , E and / or DE;
- E is selected from the group comprising COOH, COOR 14 , CONR 14 R 15 ,
- D is selected from the group comprising C 1 -C 10 -alkyl, C 2 -C 10 -alkenyl, C 2 -
- T, G are the same or independently selected from the group comprising Ci-Cio-alkyl, C 2 -Cio-alkenyl and / or C 2 -Cio-alkynyl;
- R 14 , R 15 are the same or independently selected from the group comprising H, Ci-C ⁇ -alkyl and / or aryl.
- novel heteroaryl-substituted acetone derivatives which inhibit the enzyme phospholipase A 2 can provide improved water solubility over known compounds and / or a good or even improved inhibitory action.
- the pharmaceutically acceptable salts may be base addition salts. These include salts of the compounds with inorganic bases, such as alkali metal hydroxides, alkaline earth metal hydroxides or with organic bases, such as mono-, di- or triethanolamine.
- acid addition salts in particular with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid, or with suitable organic carboxylic or sulfonic acids, or with amino acids.
- esters of the compounds are in particular physiologically readily hydrolysable esters, for example alkyl, pivaloyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethylene esters.
- alkyl includes, unless indicated otherwise, straight-chain, branched or cyclic alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, neopentyl, undecyl, dodecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, cyclohexyl etc.
- alkenyl includes straight-chain, branched or cyclic alkenyl groups, such as ethenyl, propenyl, butenyl, decenyl, heptadecenyl, cyclohexenyl, etc.
- alkynyl includes straight-chain or branched alkynyl groups, such as ethynyl, propynyl, butynyl, decynyl, heptadecinyl, etc.
- aryl includes phenyl, naphthyl, biphenyl and 5 or 6 membered heterocyclic rings containing 1 to 3 atoms selected from O, N or S and optionally fused with a benzene ring. Preference is given to phenyl and indolyl, in particular phenyl.
- halogen includes a fluorine, chlorine, bromine or iodine atom, with fluorine or chlorine atoms in particular being preferred.
- radicals such as R 4 , R 7 , R 9 and / or R 10 occur several times in a compound, these can each be chosen independently of one another.
- Q may having 1 or 2 groups independently selected from O, S, SO, SO 2, NR 9 and aryl be interrupted.
- interrupted it is meant herein that the radical, in addition to the carbon atoms of its chain, may contain such a radical both at any point within the chain and at the end of the chain, ie between the carbon chain and Ar.
- the additionally optionally present substituents in the form of 1 to 4 CI_ 6 -alkyl radicals and / or 1 or 2 aryl groups may be linked to any carbon atom of the chain.
- R 12 is CO- (CH 2 ) r -COOR 14 ,
- r is 1, 2, 3, 4 or 5.
- R 14 is selected from the group comprising H, methyl and / or ethyl.
- s, t is the same or independent 0, 1, 2, 3, 4 or 5.
- s is 0 or 1 and / or t is 0, 1 or 2.
- D is selected from the group comprising -CH 2 -aryl- (CH 2 ) 2 - and / or -CH 2 - aryl-.
- R 12 is further selected from the group comprising CO-aryl-COOH, CO-CH 2 -aryl-COOH and / or CO-CH 2 -aryl- (CH 2 ) 2 -COOH.
- Q is C 5 -C 12 -alkyl, preferably cy-Cio-alkyl. Most preferably, Q is Cs-alkyl.
- Q is OR 1 , in which R 1 is an aryl radical which may be substituted by a substituent R 4 , where R 4 is preferably CF 3 .
- R 4 is preferably connected in the para position.
- Ar is an aryl radical and preferably an aryl radical as defined above.
- Ar preferably represents a phenyl radical, which preferably connects the adjacent groups Q and O in the para position with one another.
- R 2 and R 3 together with the carbon atoms to which they are attached form a 6-membered aromatic ring, preferably a benzo ring.
- This 6-membered aromatic ring may be substituted with 1 or 2 substituents R 4 , with a substituent R 4 being preferred.
- the substituent R 4 is selected from the group comprising COOH and / or CONH 2 . More preferably R 4 is COOH.
- the compounds according to the invention have a structure according to the general formula (V) as indicated below:
- R 16 is selected from the group comprising -CO (CH 2 ) 2 COOH, -CO (CH 2 ) 3 COOH, - CO (CH 2 ) 4 COOH, -COCF 3 and / or 3-methyl-1, 2,4 oxadiazol-5-yl.
- a particularly preferred embodiment of the compounds according to the invention has the following formula (1) and / or are their pharmaceutically acceptable esters or salts:
- compounds numbered Arabic differ from Roman numbered compounds, i. they are each different compounds.
- a further particularly preferred embodiment of the compounds according to the invention has the following formula (2) and / or are their pharmaceutically acceptable esters or salts:
- a particularly preferred embodiment of the compounds according to the invention has the following formula (3) and / or are their pharmaceutically acceptable esters or salts:
- the compounds according to the invention have, at least in part, a good solubility in water.
- the compound according to the formulas (1) to (4) are characterized by a particularly good water solubility.
- the solubility of the compounds in aqueous phosphate buffer is in the range of 10 ⁇ g / ml to 500 ⁇ g / ml, preferably in the range of 150 ⁇ g / ml to 450 ⁇ g / ml, more preferably in the range of 190 ⁇ g / ml to 410 ⁇ g / ml.
- the water solubility of the compounds was determined by adding to the respective compound aqueous phosphate buffer (pH 7.4) and determining the dissolved content after shaking and centrifugation as described in Example 12.
- an improved solubility in water can provide the advantage that the compounds according to the invention can be dissolved to a greater extent, for example in the case of peroral administration in the gastrointestinal tract.
- a particular advantage of using the compounds according to the invention also results from the fact that, in order to achieve sufficient bioavailability of poorly water-soluble drugs, they must be added to solvents such as dimethylsulfoxide (DMSO) or solubilizing surfactants prior to administration. Since these solubilizers exhibit cytotoxic effects, a significant improvement in compatibility can be provided by sufficiently water-soluble drugs in which the use of solubilizers is not necessary.
- solvents such as dimethylsulfoxide (DMSO) or solubilizing surfactants
- a preferred embodiment of the compounds according to the invention has the following formula (5) and / or are their pharmaceutically acceptable esters or salts:
- a further preferred embodiment of the compounds according to the invention has the following formula (6) and / or are their pharmaceutically acceptable esters or salts:
- a preferred embodiment of the compounds according to the invention also has the following formula (7) and / or their pharmaceutically acceptable esters or salts:
- a further preferred embodiment of the compounds according to the invention has the following formula (8) and / or are their pharmaceutically acceptable esters or salts:
- a particular advantage of the compounds according to the invention results from the fact that they can provide good inhibition of the phospholipase A 2 .
- the compounds according to the formulas (6), (7) and (8) can provide a particularly good inhibition.
- a preferred embodiment of the compounds according to the invention has the following formula (12) and / or are their pharmaceutically acceptable esters or salts:
- a further preferred embodiment of the compounds according to the invention has the following formula (13) and / or are their pharmaceutically acceptable esters or salts:
- a preferred embodiment of the compounds according to the invention also has the following formula (14) and / or their pharmaceutically acceptable esters or salts:
- the effectiveness of the compounds according to the invention can be determined on the basis of the inhibition of the cytosolic phospholipase A 2 .
- cytosolic phospholipase A 2 isolated from human thrombocytes was used.
- the arachidonic acid liberated by the enzyme from 1-stearoyl-1-arachidonoyl-sn-glycero-S-phosphocholine was determined, for example by reversed-phase HPLC with UV detection at 200 nm after purification by solid-phase extraction ,
- the inhibition of the enzyme by a compound of the invention results from the Ratio of the amount of arachidonic acid produced in the presence or absence of the compound.
- the compounds according to the invention for the inhibition of cytosolic phospholipase A 2 have IC 50 values in the range from 0.001 ⁇ M to 0.5 ⁇ M, particularly preferably in the range from 0.002 ⁇ M to 0.3 ⁇ M, very particularly preferably in the range from 0, 02 ⁇ M to 0.25 ⁇ M, on.
- the IC 5 o-value of the compounds for inhibiting the cytosolic phospholipase A 2 corresponds to the concentration of the compounds that is required to reduce the enzyme activity by half.
- the IC 5 o values were calculated (from the obtained values at different concentrations of inhibiting cytosolic phospholipase A 2 by means of the probit method s. Hartke, Mutschler, DAB 9 commentary 1 S. 733-734,ticianliche Verlagsgesellschaft Stuttgart 1978 ) certainly.
- the compounds according to the invention advantageously show an effective inhibition of phospholipase A 2 .
- the compounds of the invention show effective inhibition of phospholipase A 2 and good solubility in water.
- the compounds according to the formulas (1) to (5) and (8), in particular according to the formulas (1) to (4), are characterized by an effective inhibition of phospholipase A 2 and a good solubility in water.
- the compounds are useful as medicaments for the prevention and treatment of diseases caused by products of this enzyme caused or co-caused, for example, for the treatment of diseases of the rheumatic type and for the prevention and treatment of allergic-induced diseases.
- the compounds according to the invention can thus be effective analgesics, antiphlogistics, antipyretics, antiallergics and broncholytics and are useful for thrombosis prophylaxis and prophylaxis of anaphylactic shock as well as for the treatment of dermatological disorders such as psoriasis, urticaria, acute and chronic rashes of allergic and non-allergic origin.
- the compounds according to the invention may in particular have an anti-inflammatory action.
- the compounds according to the invention can therefore be, in particular, effective antiphlogistic agents.
- a further subject of the present invention therefore relates to pharmaceutical agents or medicaments which comprise a compound of the general formula (I), in particular compounds of the formulas (1) to (8) and (12) to (14), and / or their enantiomers, Diastereomers and their pharmaceutically acceptable salts or esters include.
- the compounds of the formula (I), in particular compounds of the formulas (1) to (8) and (12) to (14) are particularly suitable for the preparation of a pharmaceutical composition or medicament for the prevention or treatment of diseases caused by increased activity the phospholipase A 2 , preferably the cytosolic phospholipase A 2 caused or co-caused.
- the invention therefore relates in particular to the use of compounds of the general formula (I) according to the invention, in particular compounds of the formulas (1) to (8) and (12) to (14) and / or their enantiomers, diastereomers and their pharmaceutically acceptable salts and / or esters for the manufacture of a pharmaceutical or medicament for the prophylactic and / or therapeutic treatment of diseases caused or contributed to by an increased activity of phospholipase A 2 .
- prophylactic treatment is understood in particular to mean that the compounds according to the invention can be administered prophylactically before symptoms of a disease occur or there is a risk of disease.
- a “prophylactic treatment” is understood to be a medicinal prophylaxis.
- Diseases caused or contributed to by an increased activity of phospholipase A 2 are preferably selected from the group consisting of inflammation, pain, fever, allergies, asthma, psoriasis, cerebral ischemia, Alzheimer's disease, chronic skin diseases, damage to the skin by UV radiation. Radiation, rheumatic diseases, thrombosis, anaphylactic shock, urticuria, acute and chronic rashes and / or endotoxin shock.
- the invention therefore relates in particular to the use of compounds of the general formula (I) according to the invention in particular compounds of the formulas (1) to (8) and (12) to (14) and / or their enantiomers, diastereomers and their pharmaceutically acceptable salts and / or esters for the manufacture of a pharmaceutical or medicament for the prophylactic and / or therapeutic treatment of diseases selected from the group consisting of inflammation, pain, fever, allergies, asthma, psoriasis, cerebral ischemia, Alzheimer's disease, chronic skin diseases, damage to the skin by UV radiation Radiation, rheumatic diseases, thrombosis, anaphylactic shock, urticuria, acute and chronic rashes and / or endotoxin shock.
- the compounds of the invention are particularly suitable for the treatment of inflammation, preferably for the treatment of inflammatory skin diseases or inflammatory diseases of the gastrointestinal tract.
- Preferred inflammatory skin diseases are selected from the group comprising contact dermatitis, atopic dermatitis, dermatitis solaris, psoriasis, urticaria, acute and chronic rashes of allergic and non-allergic causes and / or eczema.
- the term “eczema” is understood as meaning a skin disease which manifests itself in a non-infectious inflammatory reaction of the skin.
- rash is to be understood as meaning inflammatory skin changes which frequently affect larger areas of the skin.
- Preferred eczema are in particular selected from the group comprising allergic contact eczema, chronic hand eczema, atopic eczema and / or seborrheic eczema.
- Preferred rashes of allergic origin are, for example, drug eruptions.
- Particularly preferred inflammatory diseases of the gastrointestinal tract are inflammatory bowel diseases such as Crohn's disease and / or ulcerative colitis.
- the compounds of the invention are administrable as individual therapeutic agents or as mixtures with other therapeutic agents. They can be administered alone, preferably they are administered in the form of pharmaceutical agents, ie as mixtures of the active ingredients with suitable pharmaceutical carriers and / or diluents.
- the compounds or pharmaceutical agents can be administered orally, parenterally, transmucosally, pulmonarily, enterally, by inhalation, rectally or topically, especially dermally, transdermally, buccally or sublingually.
- Oral agents may, for example, be in the form of tablets or capsules, even in retarded form, and may contain conventional excipients, such as binders, for example syrup acacia, gelatin, sorbitol, tragacanth or polyvinylpyrrolidone; Fillers, for example lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; Lubricants, for example, magnesium stearate, talc, polyethylene glycol or silica; disintegrating agents such as starch or wetting agents, for example, sodium lauryl sulfate.
- binders for example syrup acacia, gelatin, sorbitol, tragacanth or polyvinylpyrrolidone
- Fillers for example lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine
- Lubricants for example, magnesium stearate, talc, polyethylene glycol or silica
- Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs or sprays, etc., or may be presented as a dry powder for reconstitution with water or other suitable vehicle.
- Such liquid preparations may contain conventional additives, for example suspending agents, flavorings, diluents or emulsifiers.
- solutions or suspensions may be employed with conventional pharmaceutical carriers.
- the compounds may be in powder, aqueous or partially aqueous solution, which may be applied in the form of an aerosol.
- Agents for topical application may, for. B. as pharmaceutically acceptable powders, lotions, ointments, creams, gels or as therapeutic systems containing therapeutically effective amounts of the inventive compounds.
- compositions suitable for topical administration are particularly preferred.
- liquid or semi-liquid preparations in particular aqueous administration forms for topical application, for example in the form of solutions or suspensions which can be administered as drops.
- More preferred are lotions, ointments, gels or creams.
- the dosage required depends on the form of the pharmaceutical agent used, the nature of the application, the severity of the symptoms, and the particular subject, especially human or animal being treated. Treatment is usually started at a dose below the optimal dose. Thereafter, the dose is increased until the optimum effect for the given conditions is achieved.
- the compounds according to the invention are administered in concentrations with which effective effects can be achieved without harmful or disadvantageous effects occurring.
- the active ingredient can be used, for example, for topical administration in the range of> 0.001% by weight to ⁇ 10% by weight, preferably in the range of> 0.1% by weight to ⁇ 5% by weight, preferably in the range of> 1 wt .-% to ⁇ 2 wt .-%, based on the total weight of the formulation, be formulated.
- Preferred dosages of the compounds according to the invention for topical administration are in the range from> 0.001 mg / cm 2 to ⁇ 2 mg / cm 2 application area, in particular skin, preferably in the range from> 0.01 mg / cm 2 to ⁇ 1 mg / cm 2 , preferably in the range of> 0.1 mg / cm 2 to ⁇ 0.5 mg / cm 2 .
- the compounds of the invention may be administered in a single dose or in multiple doses.
- the compounds according to the invention of the general formula (I) are preferably preparable according to the process disclosed in WO 2004/069797, to which reference is made in its entirety, with the exception that suitable starting materials are used to prepare the compounds according to the invention ,
- the compounds of the invention according to the general formula (I) are particularly preferably preparable by reacting a compound according to the following general formula (IV)
- the COOH groups can be protected as esters, preferably as methyl, tert-butyl, benzyl and allyl.
- the cleavage of the ester protecting groups takes place after the oxidation to the ketone by known methods.
- the keto group is protected as acetal.
- reaction solution was poured into a mixture of 5% aqueous sodium hydrogencarbonate and saturated aqueous NaCl solution (1: 1) and stirred for 10 minutes. After exhaustive extraction with diethyl ether, the combined organic phases washed three times with saturated aqueous NaCl solution. After drying over sodium sulfate, it was filtered and the solvent removed. After purification by column chromatography on silica gel (ethyl acetate / hexane 3: 7), the product was obtained as an oil.
- the preparation was carried out starting from 1.54 g (5.08 mmol) of methyl 3 - (4-methoxycarbonylbutanoyl) indo 1-5-carboxylate from stage A analogously to the synthesis of stage C of example 1.
- the reaction time was 1, 5 hours.
- the batch was purified by column chromatography on silica gel with the eluent ethyl acetate / hexane (step gradient: 1: 9-3: 7-1: 1-7: 3) to give the product as a solid.
- the preparation was carried out starting from 603 mg (1.68 mmol) of methyl 3- (4-methoxycarbonylbutanoyl) -1-oxiranylmethylindo 1-5-carboxylate from stage B analogously to the synthesis of stage D of example 1. Deviating from this, the batch was 30 Minutes at 100 0 C heated.
- the purification was carried out by column chromatography on silica gel with the eluent ethyl acetate / hexane (step gradient: 1: 2 - 1: 1). The product was obtained as a solid.
- the preparation was carried out starting from 1.30 g (4.10 mmol) of methyl 3- (5-methoxycarbonylpentanoyl) indo 1-5-carboxylate from stage A analogously to the synthesis of stage C of example 1.
- the reaction time was 1, 5 hours.
- the batch was purified by column chromatography on silica gel with ethyl acetate / hexane as eluant (step gradient: 1: 9-3: 7-1: 1) to give the product as a solid.
- the preparation was carried out starting from 900 mg (2.61 mmol) of methyl 3- (3-methoxycarbonyl-propanoyl-1-oxiranylmethylindo 1-5-carboxylate from stage A using 660 mg (2.61 mmol) 4- (4 -Trifluoromethylphenoxy) phenol and 64 mg (0.51 mmol) of A-dimethylaminopyridine analogously to the synthesis of stage D of example 1. Deviating from this, the batch was heated for 30 minutes at 100 ° C. The purification was carried out by means of column chromatography on silica gel (ethyl acetate / hexane 1: 1) The product was isolated as a solid.
- the preparation was carried out starting from 305 mg (1.02 mmol) of tert-butyl-3- (3-methyl-1,2,4-oxadiazol-5-yl) indole-5-carboxylate from stage A analogously to the synthesis of stage C. of Example 1.
- the reaction was purified by column chromatography on silica gel with eluant ethyl acetate / hexane (step gradient: 1: 9-1: 1) to give the product as a solid.
- stage A methyl 3- (5-methoxycarbonylpentanoyl) indole-5-carboxylate from stage A, corresponding to the synthesis of stage B as described in example 3.
- the preparation was carried out starting from 187 mg (0.50 mmol) of methyl 3- (5-methoxycarbonylpentanoyl) -1-oxiranylmethylindole-5-carboxylate from stage B of example 9 analogously to the synthesis in stage C of example 9 using 93 mg (0.50 mmol) of 4-phenoxyphenol and 10 mg of 4-dimethylaminopyridine. In contrast, the batch was heated at 110 ° C. for 90 minutes. The purification was carried out by column chromatography on silica gel (petroleum ether / ethyl acetate 6: 4). The product according to the formula (13) was obtained as a solid.
- the preparation was carried out starting from 145 mg (0.37 mmol) of methyl 3- (4-methoxycarbonyl-benzoyl) -1-oxiranylmethylindo 1-5-carboxylate from stage B analogously to the synthesis of stage C as indicated in Example 9 using 76 mg (0.37 mmol) of 4-octylphenol and 9 mg of 4-dimethylaminopyridine.
- the purification was carried out by column chromatography on silica gel (petroleum ether / ethyl acetate 7: 3). The product was obtained as a solid.
- the preparation was carried out starting from 95 mg (0.16 mmol) of methyl 1- [2-hydroxy-3- (4-octylphenoxy) propyl] -3- (4-methoxycarbonylbenzoyl) indo 1-5-carboxylate from stage C. analogous to the synthesis of step D as indicated in Example 9.
- the purification was carried out by column chromatography on silica gel (petroleum ether / ethyl acetate 6: 4). The product was a resinous substance.
- the content of dissolved compound was determined by means of a standard line made by injecting different amounts ranging from 5 ⁇ l to 100 ⁇ l of reference solutions 1 and 2.
- reference solution 1 2 ⁇ l of a 5 mM solution of the respective compound in dimethylsulfoxide (DMSO) were admixed with 198 ⁇ l of PBS buffer, 250 ⁇ l of acetonitrile and 50 ⁇ l of 0.1 M phosphoric acid.
- DMSO dimethylsulfoxide
- reference solution 2 ⁇ l of a 5 mM solution of the respective compound in DMSO, 398 ⁇ l of PBS buffer, 500 ⁇ l of acetonitrile and 100 ⁇ l of 0.1 M phosphoric acid were added.
- the stationary phase used was C 18 Aqua® columns from Phenomenex (Aqua®, RPl 8, 75 ⁇ 4.6 mm, 3 ⁇ m).
- the detection wavelength was 240 nm, the flow rate was 0.7 ml / min.
- As mobile phase were used for the compounds of Examples 1, 2, 3 and 7 according to the Formulas (1), (2), (3) and (7) used a mixture of acetonitrile / water / phosphoric acid (85%) in the ratio 700: 300: 1 (v / v / v) and for the compounds of Examples 4 , 5 and 8 according to the formulas (4), (5) and (8) a mixture of acetonitrile / water / phosphoric acid (85%) in the ratio 530: 470: 1 (v / v / v) and for the compound of the example 6 according to the formula (6) a mixture of acetonitrile / water / phosphoric acid (85%) in the ratio 800: 200: 1 (v / v
- the compounds of the formulas (9), (10) and (11) had a water solubility lower than 1 ⁇ g / ml.
- the efficacy of the compounds according to the invention was determined on the basis of the inhibition of cytosolic phospholipase A 2 . The determination was made, if not otherwise described below, as described in Schmitt, M .; Lehr, M., "HPLC assay with UV spectrometric detection for the evaluation of inhibitors of cytosolic phospholipase A 2 " J. Pharm. Biomed. Anal. 2004, 35, 135-142.
- the enzyme source used was cytosolic phospholipase A 2 isolated from human platelets.
- the inhibition of the enzyme activity was detected by measuring the arachidonic acid liberated in the cleavage of 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine in the presence and absence of the particular compound tested.
- the residue (50 mM Tris, 1 mM dithiothreitol, 150 mM NaCl, 1 mM CaCl 2, pH 8 at 2O 0 C) was added as much Tris buffer so that a concentration of 0.26 mM and SAPC to DOG of 0.13 mM.
- the mixture was 10 minutes in an ultrasonic bath at 35 0 C is homogenized to form Covesikeln.
- the enzyme reaction was stopped by adding 400 ⁇ l of a solution of acetonitrile / methano 1 / 0.1 M aqueous EDTA solution in the ratio 16: 15: 1 (v / v / v), this solution containing 3 ⁇ g / ml nordihydroguaiaretic acid (NDGA) (Sigma) as an antioxidant and 1.55 ⁇ g / ml 4-undecyloxybenzoic acid as an internal standard. Subsequently, the samples were placed in ice for 10 to 15 minutes and then stored at -2O 0 C until solid phase extraction.
- NDGA nordihydroguaiaretic acid
- the octadecyl solid phase extraction columns with a bed volume of 200 mg and a capacity of 3 ml were washed first with 6 ml of methanol and then with 6 ml of water.
- the samples were diluted with 2 ml of 0.005 M aqueous NaOH and then applied to the solid phase column.
- the bound arachidonic acid was eluted with 3 ⁇ 200 ⁇ l of methanol.
- the eluate was washed with 600 ⁇ l Water mixed and mixed. 100 ⁇ l of this solution was injected into the HPLC apparatus (Waters, Waters Autosampler 717plus, Waters 515 pump and Waters UV detector 2487).
- the separation column used was a Nucleosil 100-3 Cl 8 separation column (125 ⁇ 3 mm) with a Nucleosil 100-3 Cl 8 precolumn (20 ⁇ 3 mm) (CS-Chromatography Service, Langerwehe).
- the flow rate was 0.4 ml / min, the detection wavelength was 200 nm.
- the eluent used was a mixture of acetonitrile / water / phosphoric acid (85%) in the ratio 770: 230: 1 (v / v / v).
- the duration of the chromatograms was 30 minutes. The next injection was equilibrated for 15 minutes.
- the IC 50 value for the inhibition of the cytosolic phospholipase A 2 by the compounds of Examples 1 to 8 corresponding to the formulas (1) to (8) was also determined.
- the IC 5 o values were calculated (from the obtained values at different concentrations of inhibiting cytosolic phospholipase A 2 by means of the probit method s. Hartke, Mutschler, DAB 9 commentary 1 S. 733-734,ticianliche Verlagsgesellschaft Stuttgart 1978 ) certainly.
- the IC 5 o-value of the compounds for inhibiting the cytosolic phospholipase A 2 corresponds to the concentration which is necessary to reduce the activity of the enzyme by half.
- the lower the IC 50 value the more the compound inhibits the cytosolic phospholipase A 2 .
- the compound of Example 1 according to Formula (1) had an IC 50 value of 0.21 ⁇ M
- the compound of Example 2 according to Formula (2) an IC 50 value of 0.03 ⁇ M
- the compound of Example 3 according to Formula (3) an IC 50 value of 0.022 ⁇ M
- the compound of example 5 according to formula (5) an IC 50 value of 0.022 ⁇ M.
- Example 6 had an IC 50 value of 0.007 ⁇ M
- the compound of example 7 according to formula (7) an IC 50 value of 0.002 ⁇ M
- the compound of example 8 according to formula (8) an IC 50 Value of 0.007 ⁇ M.
- test animals used were Balb / c mice (Harlan Winkelmann GmbH, Borchen).
- Contact dermatitis was induced by placing 10 ⁇ l per ear of a 5% benzalkonium chloride solution (Sigma) in olive oil / acetone (1: 5) on the dorsal sides of both ears of 8 experimental animals per experimental group. This leads to a swelling of the ears.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007045476A DE102007045476A1 (de) | 2007-09-21 | 2007-09-21 | Neue heteroarylsubstituierte Acetonderivate, geeignet zur Hemmung der Phospholipase A2 |
PCT/EP2008/062552 WO2009040314A2 (de) | 2007-09-21 | 2008-09-19 | Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2215059A2 true EP2215059A2 (de) | 2010-08-11 |
Family
ID=40365415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08833836A Withdrawn EP2215059A2 (de) | 2007-09-21 | 2008-09-19 | Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100240718A1 (de) |
EP (1) | EP2215059A2 (de) |
DE (1) | DE102007045476A1 (de) |
WO (1) | WO2009040314A2 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2660704A1 (en) * | 2006-08-07 | 2008-02-14 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
EP2614144B1 (de) | 2010-09-08 | 2015-07-22 | Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH | Verwendung von phospholipase-a2-hemmern zur behandlung oder prävention einer flavivirus-infektion |
JP2014500277A (ja) * | 2010-12-09 | 2014-01-09 | アムジエン・インコーポレーテツド | Pim阻害剤としての二環式化合物 |
AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
DE102012017516A1 (de) | 2012-09-05 | 2014-03-06 | Matthias Lehr | Heteroarylsubstituierte Acetonderivate geeignet zur Behandlung von Entzündungen und Krebs |
DE102012018789A1 (de) | 2012-09-21 | 2014-03-27 | Matthias Lehr | N-Isopropylcarbamate geeignet zur Behandlung von Entzündungen und Krebs |
DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
WO2017093351A1 (de) | 2015-12-01 | 2017-06-08 | Westfälische Wilhelms-Universität Münster | Cpla2-hemmstoffe |
CN111377432B (zh) * | 2020-03-24 | 2021-07-20 | 中国科学院化学研究所 | 一种煤溶剂热处理制备层状纳米碳材料的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19638408A1 (de) * | 1996-09-19 | 1998-03-26 | Merckle Gmbh | 1-Substituierte 3-Acyl-4,5-dimethylpyrrol-2-carbonsäuren und 3-Acylindol-2-carbonsäuren sowie ihre Derivate als Hemmstoffe der cytosolischen Phospholipase A¶2¶ |
DE10305089A1 (de) * | 2003-02-07 | 2004-08-26 | Merckle Gmbh | Neue heteroarylsubstituierte Acetonderivate als Hemmstoffe der Phospholiphase A2 |
-
2007
- 2007-09-21 DE DE102007045476A patent/DE102007045476A1/de not_active Withdrawn
-
2008
- 2008-09-19 US US12/678,870 patent/US20100240718A1/en not_active Abandoned
- 2008-09-19 EP EP08833836A patent/EP2215059A2/de not_active Withdrawn
- 2008-09-19 WO PCT/EP2008/062552 patent/WO2009040314A2/de active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2009040314A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009040314A2 (de) | 2009-04-02 |
WO2009040314A3 (de) | 2009-06-04 |
DE102007045476A1 (de) | 2009-04-02 |
US20100240718A1 (en) | 2010-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2215059A2 (de) | Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2 | |
DE2705446C2 (de) | ||
DE60030574T2 (de) | Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren | |
DE69721526T2 (de) | Benzofuran carboxamide und ihre therapeutische anwendung | |
DE1695556C3 (de) | 3-Alkyl-1,2,3,4,4a,9-hexahydropyrazino[1,2-f]morphanthridinderivate | |
DE4338770A1 (de) | Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ | |
EP0148440B1 (de) | 1,3,4,5-Tetrahydrobenz[c,d]indole, ein Verfahren zu ihrer Herstellung und ihre Verwendung | |
EP0023594B1 (de) | Trans-Chinazolinderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte und Arzneimittel enthaltend solche Chinazolinderivate | |
DE4242675A1 (de) | Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung | |
EP0192056B1 (de) | Verfahren zur Herstellung von Labdan-Derivaten und ihre Verwendung als Arzneimittel | |
DE3329628C2 (de) | ||
EP0397175B1 (de) | Substituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie | |
EP0029247B1 (de) | Alkenyl-thienyl-alkancarbonsäuren und ihre Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
DE2941869C2 (de) | ||
EP0383171A2 (de) | 2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen | |
EP0002672B1 (de) | Substituierte Pyrrolidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
WO1997037977A1 (de) | Substituierte-chinolin-derivate mit antiviraler wirkung | |
DE2621507C2 (de) | ||
DE2350148A1 (de) | Thiophenderivate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
EP0103142A1 (de) | Thieno(2,3-e)-1,2-thiazin-Derivate | |
DE69909592T2 (de) | Verwendung von thiadiazolo[4,3-a]pyridine derivaten | |
DE3129718C2 (de) | ||
DE2004301A1 (de) | Phenylserinderivate | |
DE2530005C3 (de) | 6,11-Dihydrodibenzo [b,e] thiepin-Derivate und deren Salze, Verfahren zu ihrer Herstellung und diese Substanzen enthaltende pharmazeutische Zubereitungen | |
DD275689A5 (de) | Verfahren zur herstellung von enolethern von 6-chlor-4-hydroxy-2-methyl-n-(2-pyridyl)-2h-thieno(2,3-e)-1,2-thiazin-3-carbonsaeureamid-1,1-dioxid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100127 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BOVENS, STEFANIE Inventor name: LEHR, MATTHIAS |
|
17Q | First examination report despatched |
Effective date: 20110725 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20111206 |